These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21565788)

  • 21. Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine.
    Mujammami M; Hier MP; Payne RJ; Rochon L; Tamilia M
    Thyroid; 2016 Jul; 26(7):951-8. PubMed ID: 27150203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for 131 I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer : A Systematic Review and Meta-analysis.
    Park S; Bang JI; Kim K; Seo Y; Chong A; Hong CM; Lee DE; Choi M; Lee SW; Oh SW
    Clin Nucl Med; 2024 Mar; 49(3):e96-e104. PubMed ID: 38271262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy.
    Jeong SY; Lee SW; Kim WW; Jung JH; Lee WK; Ahn BC; Lee J
    Sci Rep; 2019 Apr; 9(1):5570. PubMed ID: 30944403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy.
    Kwon TE; Pasqual E; Kitahara CM; Lee C
    J Radiol Prot; 2023 May; 43(2):. PubMed ID: 37196645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review.
    Sunavala-Dossabhoy G; Petti S
    Oral Oncol; 2023 Jan; 136():106280. PubMed ID: 36525783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
    Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
    Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
    Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human thyroid-stimulating hormone to stimulate 131-I uptake for remnant ablation and adjuvant therapy.
    Sabra MM; Tuttle RM
    Endocr Pract; 2013; 19(1):149-56. PubMed ID: 23186980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
    Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
    Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for
    Gomes-Lima CJ; Chittimoju S; Wehbeh L; Dia S; Pagadala P; Al-Jundi M; Jhawar S; Tefera E; Mete M; Klubo-Gwiezdzinska J; Van Nostrand D; Jonklaas J; Wartofsky L; Burman KD
    J Endocr Soc; 2022 May; 6(5):bvac032. PubMed ID: 35356009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center.
    Tsai JR; Wu ST; Chi SY; Yang YT; Chan YC; Lim LS; Chiew YEW; Chen WC; Chen YN; Chou CK
    Kaohsiung J Med Sci; 2023 Feb; 39(2):175-181. PubMed ID: 36448726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration.
    Lee H; Paeng JC; Choi H; Cho SW; Park YJ; Park DJ; Lee YA; Chung JK; Kang KW; Cheon GJ
    PLoS One; 2021; 16(9):e0256727. PubMed ID: 34492048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
    Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
    Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals.
    Vallejo JA; Muros MA
    Rev Esp Med Nucl Imagen Mol; 2017; 36(6):362-370. PubMed ID: 28539216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.